Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2017

View Archived Issues

Kancera reports on ROR inhibitor KAN-0441571

Phase III NAVIGATE ESUS study of Xarelto stopped early for futility

Kadmon's KD-025 granted U.S. orphan drug status for cGVHD

Multiple-dosing study finds antibacterial KBP-7072 safe in healthy subjects

SYN-004 protects gut microbiome, reduces C. difficile infection in proof-of-concept study

APX-001 first-in-human results show promise

Shanghai Institute Materia Medica patents IDH1 inhibitors

Immune Sensor and collaborator divulge new hSTING agonists

Shenzhen Targetrx Biotechnology identifies HBV and HIV compounds

University of Michigan and Kura Oncology patent menin-MLL interaction inhibitors

Selexis to help advance Pelican Therapeutics' immunotherapy clinical candidates

Harmony Biosciences gains U.S. rights to pitolisant and completes equity financing

New endonucleases inhibitors presented by Biotech Innovations

Medibio to work with Otsuka to characterize sleep biomarkers related to mental illness

Emergent BioSolutions completes ACAM2000 acquisition

FDA grants new breakthrough therapy designation to Tagrisso in NSCLC

New phase I study explores BMS-986224 in healthy subjects and heart failure patients

EMA accepts Imfinzi MAA for locally advanced unresectable NSCLC

DS-2969b shows minimal disruption of normal gut flora in phase I study

Unum studies ACTR-707 with rituximab in subjects with relapsed or refractory B-cell lymphoma

Shionogi presents results on baloxavir marvoxil in combination with neuraminidase inhibitors

Australian grant supports Indo-Pacific efforts to combat tuberculosis and infectious disease

FDA announces grants for clinical trials and natural history studies

FDA approves Zilretta for osteoarthritis knee pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...